The year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective.

中文翻译：

---

基于肠促胰岛素的肥胖疗法的进展

2023 年，出现了高效胰高血糖素样肽 1 (GLP1) 单激动剂或与胰淀素受体激动剂组合的报道。2023 年还发表了在 GLP1 受体激活中添加胰高血糖素受体和/或葡萄糖依赖性促胰岛素多肽 (GIP) 受体激动作用的单分子共激动剂的结果。有趣的是，与 GLP1 激动剂缀合的拮抗性 GIP 受体抗体也被证明是有效的。